The Pharmaceutical Workforce in the Age of AI

Executive perspective

Pharmaceutical leaders face two connected decisions: where AI can improve work, and whether the organisation has the capability to use it responsibly. Treating these as separate technology and HR projects creates a gap between purchased functionality and dependable performance. Crownbridge's central proposition is that workforce readiness should be an explicit condition of AI deployment, with evidence proportionate to the consequences of the decision supported.

The UK Life Sciences Jobs Plan, published in 2026, addresses skills, hiring, sector coordination and good jobs [1]. Its relevance to individual companies is the need to connect growth ambitions to a credible capability pipeline. It does not establish that any particular business has an AI-ready workforce. That judgement requires local evidence about tasks, competence, workload and accountability.

Start with work, rather than job titles

A role can combine routine administration, scientific interpretation, relationship management and regulated approval. Automating one component does not establish that the whole role is redundant. Begin by mapping the task, the output, its users and the consequence of error. Distinguish assistance, recommendation and delegated execution. Identify whether the output contributes to a regulated record or a consequential employment decision.

For each use case, compare the present process with a proposed future process. Include the time needed to verify outputs, investigate exceptions, maintain data and train reviewers. A persuasive demonstration may hide these costs. A credible business case measures net workload and decision quality under realistic operating conditions, including poor inputs and system unavailability.

An illustrative example is an AI-assisted document review. Faster drafting may be useful, but the organisation must still decide who verifies source accuracy, detects omissions and approves the controlled document. These responsibilities should be designed before a pilot becomes normal practice. This example is a proposed management approach, not evidence of a measured productivity gain.

Build differentiated capability

A single awareness course cannot prepare the entire workforce. General users need to understand approved tools, information boundaries and the limitations of generated outputs. Scientific and operational users need task-specific evaluation skills. Reviewers need the competence and authority to reject an output. Executives need enough understanding to interrogate claims about benefit, reliability and risk.

Assess competence through realistic exercises, observed decisions and exception handling. Training attendance establishes participation; it does not establish reliable judgement. Managers should provide protected learning time and access to expertise. When a process changes, reassess whether existing qualifications, supervision arrangements and workload remain sufficient.

Capability concentration deserves explicit attention. If one data scientist understands the model and one quality specialist understands the workflow, apparent readiness may conceal fragile continuity. Cross-training, documented decisions and deputy arrangements should sit alongside technical deployment. Workforce resilience includes the ability to operate when a key person or supplier is unavailable.

Make accountability visible

The EMA and FDA's January 2026 guiding principles address good AI practice across drug development [2]. The FDA's January 2025 guidance on AI supporting regulatory decisions remains labelled draft in the source reviewed and proposes credibility assessment for a defined context of use [3]. These materials inform regulated uses; they should not be treated as universal approval for corporate AI tools.

Crownbridge recommends a named business owner for each material use case, supported by quality, scientific, technology, information-security and people expertise as relevant. Record the purpose, permitted inputs, evaluation evidence, review duties and conditions that trigger reassessment. A supplier contract is part of assurance, but cannot substitute for understanding how the organisation relies on the output.

Meaningful human review requires time, information and authority. If a reviewer is expected to approve hundreds of outputs rapidly, oversight may become ceremonial. Monitor disagreement rates and the reasons for overrides without penalising justified challenge. Low override rates are ambiguous: they can signal good performance, weak review or fear of contradicting the system.

A proposed 90-day leadership programme

Days 1-30: establish an inventory of actual AI use, including embedded software features; identify high-consequence workflows; and map critical skills. Select a small number of pilots with clear owners and baseline measures. Interview users about informal workarounds and hidden verification effort. The resulting output should be a decision register, not simply a list of tools.

Days 31-60: test selected use cases against representative tasks and realistic failures. Deliver role-specific learning and verify competence. Agree operating boundaries, escalation routes and a workable fallback. Consult affected employees and involve the appropriate professional and employment advisers where changes materially affect roles or working conditions.

Days 61-90: review evidence before scaling. Compare benefits with error rates, rework, total workload and workforce experience. Decide to expand, modify, pause or stop each pilot. This timetable is an indicative planning structure; deployment readiness depends on the workflow and applicable obligations, not elapsed days.

What the board should see

A useful board report links each material deployment to its accountable executive, intended benefit, evidence of competence and unresolved risk. Suggested measures include verified task performance, exception volumes, reviewer capacity, incidents, critical-skill coverage and resilience under outage. Aggregate training numbers or software licences should not be presented as evidence of operating readiness.

Boards should ask: which decisions now depend on AI; who can challenge them; where did verification effort increase; and what evidence would cause management to suspend a use case? The objective is an operating system in which scientific judgement and human accountability remain visible as technology changes. Crownbridge's proposed framework is an advisory synthesis for discussion, not a validated maturity instrument or a regulatory standard.